BioXcel Therapeutics shares surge 20.61% intraday after announcing sNDA submission for at-home use of IGALMI.

Bioxcel Therapeutics surged 20.61% intraday following the announcement of plans to submit a supplemental New Drug Application (sNDA) this month for IGALMI® to treat acute agitation associated with bipolar disorders or schizophrenia in the at-home setting. The company emphasized that this submission could lead to FDA approval as early as 2026, positioning IGALMI as the first FDA-approved at-home treatment for this indication, where no current options exist. The news highlights regulatory progress and potential market expansion, with the CEO noting the therapy’s importance for patients and caregivers. The stock’s sharp rise reflects investor optimism about the drug’s commercial prospects and the company’s strategic focus on unmet medical needs in neuropsychiatry.